Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Current Status of Circulating Tumor Cells and Circulating Tumor DNA

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2019 Jun 28

PMID 31243883

Citations 47

Authors

Jee-Soo Lee

Sung Sup Park

Young Kyung Lee

Jeffrey A Norton

Stefanie S Jeffrey

Affiliations

Soon will be listed here.

Abstract

Reliable biomarkers are required to evaluate and manage pancreatic ductal adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and can be relatively easily obtained from minimally invasive liquid biopsies for serial assays and characterization, thereby providing a unique potential for early diagnosis, forecasting disease prognosis, and monitoring of therapeutic response. In this review, we provide an overview of current technologies used to detect circulating tumor cells and circulating tumor DNA and describe recent advances regarding the multiple clinical applications of liquid biopsy in pancreatic ductal adenocarcinoma.

Citing Articles

Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review.

Salahi-Niri A, Zarand P, Mansouri N, Rastgou P, Yazdani O, Esbati R Health Sci Rep. 2025; 8(3):e70412.

PMID: 40051490 PMC: 11882395. DOI: 10.1002/hsr2.70412.

Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine.

Bamodu O, Chung C, Pisanic 2nd T J Liq Biopsy. 2025; 2:100126.

PMID: 40028482 PMC: 11863985. DOI: 10.1016/j.jlb.2023.100126.

Informatics strategies for early detection and risk mitigation in pancreatic cancer patients.

Jin D, Khan N, Gu W, Lei H, Goel A, Chen T Neoplasia. 2025; 60:101129.

PMID: 39842383 PMC: 11763847. DOI: 10.1016/j.neo.2025.101129.

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma.

Gotze J, Meissner K, Pereira-Veiga T, Belloum Y, Schneegans S, Kropidlowski J J Exp Clin Cancer Res. 2025; 44(1):14.

PMID: 39815324 PMC: 11737273. DOI: 10.1186/s13046-024-03262-x.

Oligoribonucleotide interference-PCR-based methods for the sensitive and accurate detection of mutations.

Fujita H, Fujita T, Ishido K, Hakamada K, Fujii H Biol Methods Protoc. 2024; 9(1):bpae071.

PMID: 39478810 PMC: 11522869. DOI: 10.1093/biomethods/bpae071.

References

Kamarajah S, Burns W, Frankel T, Cho C, Nathan H . Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 2017; 24(7):2023-2030. DOI: 10.1245/s10434-017-5810-x. View

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C . Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117(7):1017-1025. PMC: 5625666. DOI: 10.1038/bjc.2017.250. View

Kidess E, Jeffrey S . Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?. Genome Med. 2013; 5(8):70. PMC: 3979136. DOI: 10.1186/gm474. View

Ying H, Dey P, Yao W, Kimmelman A, Draetta G, Maitra A . Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016; 30(4):355-85. PMC: 4762423. DOI: 10.1101/gad.275776.115. View

Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N . Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016; 115(1):59-65. PMC: 4931379. DOI: 10.1038/bjc.2016.175. View

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

Kalinich M, Haber D . Cancer detection: Seeking signals in blood. Science. 2018; 359(6378):866-867. PMC: 6469388. DOI: 10.1126/science.aas9102. View

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E . In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and Point Mutations in Circulating Tumor Cells. Clin Chem. 2018; 64(3):536-546. DOI: 10.1373/clinchem.2017.281295. View

Zhang J, Li S, Liu F, Zhou L, Shao N, Zhao X . SELEX aptamer used as a probe to detect circulating tumor cells in peripheral blood of pancreatic cancer patients. PLoS One. 2015; 10(3):e0121920. PMC: 4370620. DOI: 10.1371/journal.pone.0121920. View

10.

Passerini R, Cassatella M, Boveri S, Salvatici M, Radice D, Zorzino L . The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol. 2012; 138(2):281-7. DOI: 10.1309/AJCPOPNPLLCYR07H. View

11.

Chang M, Chang Y, Chen J, Jeng Y, Yang C, Tien Y . Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem. 2016; 62(3):505-13. DOI: 10.1373/clinchem.2015.248260. View

12.

Hanania A, Bantis L, Feng Z, Wang H, Tamm E, Katz M . Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget. 2016; 7(52):85776-85784. PMC: 5349873. DOI: 10.18632/oncotarget.11769. View

13.

Zill O, Banks K, Fairclough S, Mortimer S, Vowles J, Mokhtari R . The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018; 24(15):3528-3538. DOI: 10.1158/1078-0432.CCR-17-3837. View

14.

Rothe F, Laes J, Lambrechts D, Smeets D, Vincent D, Maetens M . Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014; 25(10):1959-1965. DOI: 10.1093/annonc/mdu288. View

15.

Chun Y, Pawlik T, Vauthey J . 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol. 2017; 25(4):845-847. DOI: 10.1245/s10434-017-6025-x. View

16.

Diaz I, Nocon A, Mehnert D, Fredebohm J, Diehl F, Holtrup F . Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One. 2016; 11(11):e0166354. PMC: 5104415. DOI: 10.1371/journal.pone.0166354. View

17.

Gogoi P, Sepehri S, Zhou Y, Gorin M, Paolillo C, Capoluongo E . Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS One. 2016; 11(1):e0147400. PMC: 4726586. DOI: 10.1371/journal.pone.0147400. View

18.

Markus H, Contente-Cuomo T, Farooq M, Liang W, Borad M, Sivakumar S . Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018; 8(1):7375. PMC: 5943304. DOI: 10.1038/s41598-018-25810-0. View

19.

Kamisawa T, Wood L, Itoi T, Takaori K . Pancreatic cancer. Lancet. 2016; 388(10039):73-85. DOI: 10.1016/S0140-6736(16)00141-0. View

20.

Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B . Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol. 2016; 10(4):635-43. PMC: 5423145. DOI: 10.1016/j.molonc.2015.11.012. View